Fundamental limit of the alpha-synuclein immunohistochemistry using the endoscopic biopsy from the gastrointestinal tract as a biomarker for Parkinson disease: a case-control study
Objective: To investigate significance of the Lewy pathology in biopsy and surgical specimen in the gastrointestinal (GI) tract as an in-vivo biomarker for Parkinson disease (PD). Background: Alpha-synuclein…Serum lipid profile in Parkinsons disease patients from Southern Spain
Objective: Our first aim was to evaluate differences in the blood lipid profile levels between Parkinsons disease (PD) patients and healthy controls (HC). Secondly, in…Genetic, epigenetic and expression profiles in alpha-synucleinopathies
Objective: To determine whether each of the alpha-synucleinopathies has distinct methylation and/or expression profiles that distinguishes them from other disorders in this class. Background: The…Modeling Parkinson’s disease pathology by combined injection of fibrilar and monomeric α-synuclein in rat brain
Objective: Development of a fast and progressive Parkinson’s disease (PD) model in rat Background: α-Synuclein is a common link between sporadic and familial PD. Rodent…Antibody binding differences in alpha-synuclein from Parkinson’s disease and multiple system atrophy
Objective: Determine whether alpha-synuclein derived from Parkinson's disease (PD) and multiple system atrophy (MSA) brains has different conformations as defined by biochemical and antibody-based approaches. Background: There…Full sequencing and GWAS markers analysis of SNCA in RBD and progression to synucleinopathies.
Objective: To study the role of SNCA variants in REM sleep Behavior Disorder (RBD) and progression to synucleinopathies. Background: Individuals with properly diagnosed idiopathic RBD…Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration
Objective: To determine the relationship between synucleinopathy, neuroinflammation and nigrostriatal degeneration using the rat α-syn PFF model. Background: No therapy exists to halt or slow…In silico predictive analytics: accelerating identification of potential disease-modifying compounds for Parkinson’s disease
Objective: To use an in silico screen to identify compounds that have potential to reduce α-synuclein (aSyn) oligomers and are amenable to drug repurposing for…CSF, plasma and saliva alpha-Synuclein in moderately advanced Parkinson’s disease cohort: the BioFIND study
Objective: To test if alpha-synuclein (α-syn) levels in CSF, plasma and saliva predict PD status in the BioFind cohort, and to test whether α-syn levels…Alpha-synuclein enhances histone H3 lysine-9 dimethylation
Objective: To explore the nuclear function of alpha-synuclein (αS). Background: αS is a protein linked to Parkinson’s disease (PD) and related neurodegenerative disorders. It is…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 51
- Next Page »